Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Lumora vs Oak

Lumora
Graded #205

Lower grade

vs+9.800000000000011
Oak
Graded #42

Higher grade

The verdict

Oak takes it — 75.9/100 to 66.1/100.

Oak grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The cheapest published prices on the board, sold as a package with no membership fee.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueOak +60
36
96
Dose & formulationLumora +13
75
62
Clinical oversightLumora +21
87
66
Labs & monitoringLumora +18
76
58
FulfillmentOak +14
74
88
Contract termsOak +33
55
88
Lumora · left barOak · right bar

The numbers

MetricLumoraOak
WeighScore66.1/10075.9/100
GradeCC
Scorecard rank#205#42
Semaglutide$199/mo (starting dose, plus a separate fee, compounded)From $119/mo
Tirzepatide$299/mo (starting dose, compounded)From $185/mo
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Lumora

Graded #205 · C

Strengths

  • Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
  • Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
  • LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
  • Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
  • Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141

Where it loses points

  • Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
  • Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
  • Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
  • No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
  • Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list
Oak

Graded #42 · C

Strengths

  • Lowest published prices here — semaglutide from $119/mo, tirzepatide from $185/mo
  • One price across every dosage, so titrating up costs no more
  • No membership or subscription fee, and free shipping
  • All 50 states, offered in Spanish as well as English

Where it loses points

  • Same-day approval with no video call means very little clinical contact before a prescription
  • No published lab or monitoring programme
  • Injection only, and no brand-name lane
  • Sold as packages, so re-ordering is on you

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard